tepadina

Tepadina Instructions
Common name: Thiotepa
Trade name: Tepadina
All names: Thiotepa, Thiotepa, Tepadina

Indications:
Mainly treat ovarian cancer, breast cancer, bladder cancer and digestive tract cancer.
For pretreatment before autologous or allogeneic hematopoietic progenitor cell transplantation in adult and pediatric patients.
tepadina said that in combination with other chemotherapy agents:
With or without total body irradiation (TBI), conditioning before allogeneic or autologous hematopoietic stem cell transplantation (HPCT) in adult and pediatric patients with hematologic diseases;
High-dose chemotherapy with the support of HPCT is appropriate when used to treat solid tumors in adult and pediatric patients.

Usage and dosage:
Intravenous or intramuscular injection (single medication): 10 mg (0.2 mg/kg) once a day, then change to 3 times a week after 5 consecutive days, with a total dose of 300 mg in one course of treatment.
Intrathoracic, abdominal or pericardial injection: 10 to 30 mg once, 1 to 2 times a week.
Intravesical instillation: After each emptying of urine, insert the urinary catheter into the bladder and inject 60mg into the bladder, dissolved in 60ml of normal saline, 1 to 2 times a week, 10 times as a course of treatment.
Arterial injection: 10 to 20 mg each time. The usage is the same as intravenous injection.

Adverse reactions:
Mainly bone marrow suppression and gastrointestinal reactions, but generally mild. This product can cause azoospermia in male patients, amenorrhea in females, and a few patients may have fever and rash.
Infection, allergy, skin toxicity, hepatic veno-occlusive disease, central nervous system toxicity, carcinogenicity

Contraindications:
Contraindicated in those allergic to this product, those with severe bone marrow suppression, and those with severe liver and kidney function impairment.
This product has teratogenic and mutagenic effects and is contraindicated by pregnant women. Not recommended for lactating women.

Notes:
1. This drug should be avoided in the first 3 months of pregnancy because it has mutagenic or teratogenic effects and can increase fetal death and congenital malformations.
2. It should be used with caution or at a reduced dosage in the following situations: bone marrow suppression, liver function impairment, infection, renal function impairment, tumor cell infiltration into the bone marrow, history of urinary tract stones and gout.
3. During the medication period, peripheral blood, white blood cells, platelets, liver and kidney functions should be checked regularly every week. Corresponding examinations should be continued within 3 weeks after stopping the drug to prevent continued severe bone marrow suppression.
4. When liver and kidney function is poor, a lower dose of this product should be used.
5. In order to prevent uric acid nephropathy or hyperuricemia in patients with leukemia and lymphoma, large amounts of fluids (or) allopurinol can be given.
6. Try to avoid using it in combination with other alkylating agents, or using it at the same time.

Storage:
Shade, airtight, and store in a cold place.

Mechanism of action:
Thetepa is a cell cycle non-specific drug. Under physiological conditions, it forms an unstable ethyleneimine group and has a strong cytotoxic effect. Thiotepa is a multifunctional alkylating agent that can inhibit the synthesis of nucleic acids, cross-link with DNA, interfere with the functions of DNA and RNA, and change the function of DNA, so it can also cause mutations. In vitro tests have shown that it can cause chromosomal aberrations, and carcinogenicity was clearly seen in studies on mice, but it is not yet clear in humans. In recent years, it has been proven that this product affects the content of pituitary follicle-stimulating hormone.

Safety and efficacy:
Thiotepa is a synthetic anti-tumor drug and a representative of ethylene imine alkylating agents, which is effective against a variety of solid tumors. Experimental studies have proven that Tepadina has a significant inhibitory effect on a variety of animal tumors and inhibits DNA synthesis. In tissue culture, Tepadina can inhibit mitosis of animal embryonic cells, human cells and tumor cells. According to data from multiple clinical trials, the therapeutic effect of Thiotepa is very significant. The successful development of this drug is good news for many patients.
Tepadina can effectively treat ovarian cancer. It is suitable for non-radical ovarian cancer surgery/abdominal dissemination with ascites/small bone metastasis/pulmonary metastasis with pleural effusion, etc. The effective rate of this drug in treating ovarian cancer can reach 40%. Tepadina can also treat breast cancer. It is mainly suitable for adjuvant treatment after non-radical surgery/skin metastasis/pulmonary metastasis with pleural effusion/radical surgery. The effective rate of tepadina in treating breast cancer is 60%.